1 / 5

IGRAs: Should they replace the TST in the identification of latent tuberculosis?

IGRAs: Should they replace the TST in the identification of latent tuberculosis?. Objectives • Describe how interferon-gamma release assays (IGRAs) work. • List three advantages and disadvantages of IGRA in comparison to tuberculin skin testing (TST).

bobby
Download Presentation

IGRAs: Should they replace the TST in the identification of latent tuberculosis?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. IGRAs: Should they replace the TST in the identification of latent tuberculosis? • Objectives • • Describe how interferon-gamma release assays (IGRAs) work. • • List three advantages and disadvantages of IGRA in comparison to tuberculin skin testing (TST). • • Identify populations where IGRA testing may be of benefit in the management of latent tuberculosis infection. • AllenKraut, MD, frcpc • Medical Director, Occupational Health WRHA WRHA T8 Forum April 12.2012 • Conflict of Interest • • Received Quantiferon TB Gold in Tube Tubes from Cellestis as part of a research study.

  2. ■ i • [:i,i | v, .o' <«0 »0 35 lll'mi ami lK1 o( Nil Any NO0J!*»" MO <0 35iU'.tiIo-<2SSoINi iOi ndulemi nale" 58 0 <0 35 IU rvi o- <25S d Ni <05 >B0 Any Arty SJVSSJff*"* • New Technologies - Blood tests • • Interferon Gamma Release Assays (IGRAs) • • White blood cells in people infected with TB release Gamma interferon • •  Detect specific Mycobacterium TB proteins • • Less likely to give false positive results • • Can not differentiate latent and active disease • Some issues with TST • •  Difficulty reading test. • • 6mm inter reader variability • •  Not specific for Mycobacterium Tuberculosis • • False +ve with BCG or Atypical Mycobacterium • •  Requires two visits days apart for reading • • Subject to boosting • •  Definition of positive test depends on circumstances • Interferon Gamma Release Assays (IGRAs) • • Quantiferon-TB Gold In-Tube Assay • •  ESAT-6, CFP - 10, TB7.7 • •  Measure IFN- Gamma ELISA • • T-spot.TB Assay • •   ESAT-6, CFP - 10 • • Count spots which are related to the number of cells releasing Gamma Interferon.

  3. K A *-!.-*...*..•«•• ------_. Y Q-- • n«-*i«*.«. Blood needs to be C processed within 8 hours. Can be O KKCSSt extended to 32 hours by adding a specific reagent - T-spot.TB assay TspotTB • PY*      .- • Rl • i ■ IGRAs • IGRAs in HCP • • Significant discordance is found between TST and IGRA positivity rates in healthcare workers (HCWs), • • TST+/IGRA- - BCG vaccinations. • •  IGRAs seem to correlate with markers of exposure in HCWs • • Serial testing results limited • • CCDRVol36 June 2010 • Advantages • •   More specific for Mycobacterium TB. • " Atypical mycobacteria • • M. koniosii. M siulgoi. and M matmum • •   Single patient encounter • •   Objective criteria for positive response Disadvantages • •   Requires blood draw • •   Requires sophisticated equipment • •   Elements of processing time sensitive • •   Results may not be readily available • •   ? Immunosuppressed -Tspot.TB may be better • •   Higher direct costs, but may have lower costs if include all required follow up and treatment • 6,530 healthcare workers (HCWs) screened for latent tuberculosis infection • AS 10 I It U > .crcou-d »iiMJI'l <;i f • 25 fold increase in conversion rate using QFT vs TST Direct costs • • QFTTB Gold in Tube $436,096 • • TST $78,360. Indirect costs • • confirmatory TSTs, additional chest radiographs, extra nurse assessments, and examinations. • Total costs $521,890 :»^r-~u>cb>Qn <-ii IIM h(«of> F"«>n»cl I 13 (idiimcti liw folk ixctoimoithfji i-tun I lciicd«ilh ISI I • (Kc»cfliJi         iKriiuinolpio'tivcJ              (Ncjjlivcl ll'.i.mvcl IDfdncK • Inlrctun Control and Hoipi|alCp«l«niiiloa 2010:11.HIS !>8S

  4. IGRA result ♦ve -ve TST result «ve LTBI low risk don't treat. High risk treat. -ve High Risk Treat Low risk ?? No LTBI • IGRA performance in contacts and outbreak investigations • •  IGRAs correlate well with surrogate markers of exposure • in contact and outbreak settings, but not necessarily better than TST in all populations. • •  Correlation between IGRA results and surrogate markers of • exposure is better than TST in low incidence settings where BCG has been commonly used; this is not evident in high incidence countries. • •  Discordance between TST and IGRAs are almost always • found. Concordance levels seem to vary when IGRA and TST cut-off points are changed • Are IGRA results constant? • • Reversion rates are higher when baseline IFN-y levels are just above the cut-off point and when baseline results are discordant (i.e. TST-/IGRA+). • • Reversion rates low when baseline IFN-y levels are high and when baseline results are concordantly positive (TST+/IGRA+). • CTS recommendations • • Immunocompromised •TSTfirst test • • If TST -ve IGRA can be used and if +ve consider treatment • • Degree of benefit unknown in TST-ve IGRA+ve. • • T Spot .TB may be better in an immunosuppressed population • CTS recommendations • • IGRAs should not be used in the diagnosis of active TB in adults may be a supplemental aide in dx in children. • • Contacts- • • IGRAs can be used to confirm +ve TSTS • • IGRAS or TSTs can be used to identify +vesforTXforLTBI • International Guidelines • Clin Microbiol Infect 2011; 17: 806-814 • •   33 guidelines and position papers from 25 countries and two supranational organizations. • •   The results show considerable diversity in the recommendations on IGRAs • •   (i) two-step approach of tuberculin skin test (TST) first, followed by IGRA either when • •   the TST is negative (to increase sensitivity, mainly in immunocompromised individuals). • •   or when the TST is positive (to increase specificity, mainly In BCG vaccinated individuals); • •   (ii) Either TST or IGRA, but not both; • •   (iii) IGRA and TST together (to increase sensitivity), • •   (iv) IGRA only, replacing the TST. • •   Overall, the use of IGRAs is increasingly recommended,

  5. International Guidelines • Clin Microbiol Infect 2011; 17:806-814 • •  Most of the current guidelines do not use objective. transparent methods to grade evidence and recommendations, and • •  Do not disclose conflicts of interests • •  future IGRA guidelines must aim to be transparent, evidence-basea. periodically updated, and free of financial conflicts and industry involvement. Conclusions • IGRAs will help identify who needs treatment for LTBI • Exact role need to be determined • • Very helpful in low risk TST +ve BCG population • •  ? immunosuppressed population • •  Useful for population that is hard to follow Definition of positive reaction may have to vary depending on situation of testing

More Related